Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
- Oral Flu Drug Prescriptions 11 Times More than Pre-COVID: July Survey
August 29, 2023
- Nichi-Iko Winds Up Avastin Biosimilar Deal with Sandoz
August 29, 2023
- Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
August 29, 2023
- Taiho Gets Options to French Firm’s GnT-V-Targeted Cancer Drug in Asia
August 28, 2023
- FDA Grants Priority Review for Xtandi in Earlier Type of Prostate Cancer
August 25, 2023
- Ayumi Walks Away from JPMA, Plans to Join JGA
August 23, 2023
- Mounjaro Makes Comeback as No 1 in GP Promotion, Tarlige Tops HP List in June: Intage
August 23, 2023
- Tecentriq/Cabometyx Combo Extends PFS in Prostate Cancer Trial: Takeda
August 23, 2023
- Iveric Bio’s AMD Drug Accepted for EMA Review: Astellas
August 21, 2023
- Opdivo Yet Again Frontrunner, Keytruda Follows in April-June: IQVIA
August 18, 2023
- Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
August 18, 2023
- Takeda Files cTTP Therapy ADAMTS-13 in Japan
August 18, 2023
- Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
August 17, 2023
- BMS Unit Wins Japan Approval for Sprycel Authorized Generic
August 17, 2023
- Healios Sets Up R&D Subsidiary for eNK Cells
August 16, 2023
- Moderna Japan Chief to Bow Out at Year-End for Personal Reasons
August 14, 2023
- Novo Nordisk Files Once-Weekly Basal Insulin in Japan
August 10, 2023
- Astellas to Open New Life Sciences Facility in Greater Boston Area
August 10, 2023
- Japan Ethical Drug Sales Up 8.8% in June: Crecon
August 10, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…